PT  - JOURNAL ARTICLE
AU  - Nierengarten, Mary Beth
ED  - Bansback, Nick
TI  - Triple Therapy More Cost-effective than Biologic First in Patients Who Fail MTX
DP  - 2014  01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 51
4099  - http://mdc.sagepub.com/content/14/51/13.short
4100  - http://mdc.sagepub.com/content/14/51/13.full
AB  - For patients with rheumatoid arthritis (RA) who fail methotrexate (MTX), using a biologic instead of triple therapy first is not a cost-effective use of health care resources due to the large additional costs for very small benefits. This article presents the results of a randomized noninferiority trial that compared the cost-effectiveness of treating patients who fail MTX with a biologic first or adding triple therapy followed by a biologic.